Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsIntroduction of SLC47A2
SLC47A2 encoded by SLC47A2 gene, also known as MATE2, is a member of the MATE (multidrug and toxic compound extrusion) family of transporters. It is responsible for the solute transport and its substrates are diverse including tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methyl nicotinamide, metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, and ganciclovir. SLC47A2 is primarily expressed in the kidney.
| Basic Information of SLC47A2 | |
| Protein Name | Multidrug and toxin extrusion protein 2 |
| Gene Name | SLC47A2 |
| Aliases | MATE2, MATE2K, MATE2-B, MATE2-K |
| Organism | Homo sapiens (Human) |
| UniProt ID | Q86VL8 |
| Transmembrane Times | 13 |
| Length (aa) | 602 |
| Sequence | MDSLQDTVALDHGGCCPALSRLVPRGFGTEMWTLFALSGPLFLFQVLTFMIYIVSTVFCGHLGKVELASVTLAVAFVNVCGVSVGVGLSSACDTLMSQSFGSPNKKHVGVILQRGALVLLLCCLPCWALFLNTQHILLLFRQDPDVSRLTQDYVMIFIPGLPVIFLYNLLAKYLQNQGWLKGQEEESPFQTPGLSILHPSHSHLSRASFHLFQKITWPQVLSGVVGNCVNGVANYALVSVLNLGVRGSAYANIISQFAQTVFLLLYIVLKKLHLETWAGWSSQCLQDWGPFFSLAVPSMLMICVEWWAYEIGSFLMGLLSVVDLSAQAVIYEVATVTYMIPLGLSIGVCVRVGMALGAADTVQAKRSAVSGVLSIVGISLVLGTLISILKNQLGHIFTNDEDVIALVSQVLPVYSVFHVFEAICCVYGGVLRGTGKQAFGAAVNAITYYIIGLPLGILLTFVVRMRIMGLWLGMLACVFLATAAFVAYTARLDWKLAAEEAKKHSGRQQQQRAESTATRPGPEKAVLSSVATGSSPGITLTTYSRSECHVDFFRTPEEAHALSAPTSRLSVKQLVIRRGAALGAASATLMVGLTVRILATRH |
Function of SLC47A2 Membrane Protein
SLC47A2/MATE2 is an organic cation/proton exchanger that plays an important role in the renal elimination of toxic electrolytes including endogenous and exogenous, through urine and bile. Its substrates are diverse including many cationic drugs and endogenous compounds. Many studies have indicated that SLC47A2 plays an important role in metformin (a drug for diabetes treatment) pharmacokinetics. It is associated with metformin disposition and response through mediating the transport and excretion of metformin into the urine and bile. A gain-of-function promoter polymorphism (rs12943590 G>A) of SLC47A2 gene is associated with glucose-lowering effects of metformin in type 2 diabetes patients. In addition, compared to the paired adjacent nontumor tissues, the expression of SLC47A2 is significantly decreased in the renal cell carcinoma (RCC) tissue at low tumor node metastasis stage, suggesting that SLC47A2 inhibition may enhance the risk of RCC.
Fig.1 The structural model of human MATE2-K is presented: side view (A) and top view (B). (Nishimura, 2014)
Application of SLC47A2 Membrane Protein in Literature
The article reports that the high MATE2 expression may result in resistance to the anti-proliferative effect of metformin and should be considered as a negative predictive biomarker in clinical trials.
In the study, results show that the expression of SLC47A2 is significantly decreased in the renal cell carcinoma (RCC) tissue compared to the paired adjacent nontumor tissues at low tumor node metastasis stage. Thus, it is proposed that the inhibition of SLC47A2 may increase the susceptibility of RCC.
The investigation reveals that MATE2-K is involved in the poor response to metformin in patients with diabetes.
Results of the study show that heterozygous MATE variants have little effect on the disposition of metformin in diabetic patients.
This metformin pharmacokinetic study determines the association between MATE2-K promoter haplotypes and metformin pharmacokinetics.
SLC47A2 Preparation Options
Based on the versatile Magic™ membrane protein production platform, Creative Biolabs can help you to obtain the best soluble and functional target protein to make your project a success. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SLC47A2 antibody development services.
As a forward-looking biotech company as well as a leading custom service provider in the field of membrane protein, Creative Biolabs has won good reputation among our worldwide customers for successfully accomplishing numerous challenging projects including generation of many functional membrane proteins. According to your special requirements, our experienced scientists are able to offer customized services. Please feel free to contact us for more information.
Reference
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
